Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 12/20 | 0.48 |
| ▸ | PRKCH | P24723 | 12/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 11/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 10/20 | 0.48 |
| ▸ | PRKCA | P17252 | 10/20 | 0.48 |
| ▸ | PRKCB | P05771 | 7/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.46 |
| ▸ | LATS1 | O95835 | 6/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327386 | 0.76 | PRKCD (0.56) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3327383 | 0.75 | PRKCD (0.45) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3325550 | 0.73 | PRKCD (0.55) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3325544 | 0.73 | PRKCD (0.55) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3327787 | 0.71 | PRKCD (0.55) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3327421 | 0.70 | PRKCZ (0.59) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL13337105 | 0.70 | PRKCH (0.66) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3225927 | 0.70 | MEN1 (0.41) | CYP1A2 | |
| SCHEMBL3326355 | 0.69 | PRKCD (0.58) | PRKCDPRKCHPRKCEPRKCQPRKCA | |
| SCHEMBL3326372 | 0.67 | PRKCH (0.75) | PRKCDPRKCHPRKCEPRKCQPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | VAN EIS MAURICE | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130469-A1 | 2, 6-NAPHTHRIDINE DERIVATIVES | PKN1, PKN2, CDK9 | PRKCD 63/4885PRKCH 22/4885PRKCE 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.